There are currently 1877 clinical trials in Philadelphia, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pennsylvania, Children's Hospital of Philadelphia, Fox Chase Cancer Center and Thomas Jefferson University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy
NCT06747845
Recruiting
The main goal of this study is to look at the effectiveness and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib and ipilimumab, on the patients and their pancreatic cancer. This study will involve two different treatment arms. In Arm A, patients will receive niraparib plus ipilimumab. In Arm B, patients will receive standard chemotherapy. The main questions the study aims to answer are: * Does niraparib plus ipilimumab slow down tumor growth in patients with pancrea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: Pancreatic Adenocarcinoma Metastatic
Register for Updates
Home-Based Exercise Program Using Mobile Technology After Left Ventricular Assist Device Implantation
NCT06291922
Recruiting
The goal of this clinical trial is to evaluate the effects of a home-based exercise program using mobile technology on physical activity and capacity, frailty and muscle mass, and quality of life in patients with a newly implanted HeartMate 3 left ventricular assist device (HM3 LVAD). Researchers will compare the effects of an exercise intervention vs. usual care on physical activity and capacity, frailty and muscle mass, and quality of life.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Heart Failure
Register for Updates
Opioid Treatment and Peer Recovery Support
NCT04978168
Recruiting
Determine whether a facilitated local change team intervention improves a probation organization's client-level medication for opioid use disorder (MOUD) outcomes and implementation outcomes relative to baseline across multiple sites. Determine whether client-level outcomes are further enhanced by the introduction of Peer Support Services.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Temple University, Philadelphia, Pennsylvania
Conditions: Opioid-use Disorder
Register for Updates
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
NCT06564844
Recruiting
This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Non-small Cell Lung Cancer
Register for Updates
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
NCT06369467
Recruiting
This study is researching an experimental drug called linvoseltamab combined with another drug called dupilumab. The study is looking at patients who have severe IgE-mediated food allergy. If the patient has an allergy, the body's defense system (immune system) overreacts to an allergen (eg, certain foods like peanuts, milk, shellfish) by making antibodies called IgE. An antibody is a protein that allows the immune system to find and fight off things the body does not recognize (allergens). IgE... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
05/08/2025
Locations: The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Food Allergy
Register for Updates
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
NCT06190951
Recruiting
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with cemiplimab alone. These types of immunotherapy study drugs are collectively known as immune checkpoint inhibitors. Immunotherapies are treatments that use the immune system to recognize and kill cancer cells. The study is focused on participants with a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Melanoma
Register for Updates
Clinical Study of the inQB8 TTVR System
NCT06611579
Recruiting
Prospective, multi-center study to assess safety and performance of the inQB8 MonarQ Tricuspid Valve Replacement System.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Penn Presbyterian Medical Center, Philadelphia, Pennsylvania
Conditions: Tricuspid Valve Regurgitation
Register for Updates
Comparison of Uncomplicated Candidemia Therapy Duration in Children
NCT05763251
Recruiting
The goal of this clinical trial is to compare antifungal therapy duration in pediatric uncomplicated candidemia. The specific aims are: * Compare the desirability of outcome ranking in children with uncomplicated candidemia randomized to 7 additional days of antifungal therapy (standard-course) versus no additional antifungal therapy (short-course) after already receiving 7 days of echinocandin therapy. * Compare the 14-day desirability of outcome measure for subjects with a negative and those... Read More
Gender:
ALL
Ages:
Between 120 days and 18 years
Trial Updated:
05/07/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Invasive Candidiasis
Register for Updates
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04068597
Recruiting
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Penn Medicine - Abramson Cancer Center Perelman, Philadelphia, Pennsylvania
Conditions: Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
Register for Updates
Airway Data Collection With the Entarik Feeding Tube System
NCT06760572
Recruiting
The purpose of this study is to evaluate the airway detection performance of the Entarik Feeding Tube System, and to collect data when the Entarik Feeding Tube is in the Airway for device development.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Temple University Hospital, Philadelphia, Pennsylvania
Conditions: Healthy
Register for Updates
Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry
NCT06974981
Recruiting
The COPD in LCS Registry will identify and characterize individuals who have functional or radiographic evidence of COPD and are receiving lung cancer screening. Clinical information will be obtained from study participants including symptom burden, lung cancer risk, spirometry, imaging characteristics, and peripheral blood eosinophils.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
05/07/2025
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: COPD - Chronic Obstructive Pulmonary Disease
Register for Updates
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
NCT05498272
Recruiting
Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavorable intermediate-risk or high-risk localized prostate cancer. All patients must have confirmed germline or somatic select HRR alterations. Germline and somatic mutation testing will be performed as part of commercially available CLIA assays and will be validated on a uniform platform centrally all... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Penn Medicine Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma, High-Risk Cancer
Register for Updates